Dr. Sytkowski brings to Callisto considerable experience in oncology both as a practicing physician and through his industry experience in world-wide clinical development of cancer therapeutics. Dr. Sytkowski is currently Associate Professor of Medicine at Harvard University has agreed to serve as Callisto's Clinical Trial Advisor and Medical Safety Monitor. Dr. Sytkowski will advise on Callisto's expanding clinical programs to develop its anticancer drugs Atiprimod and L-Annamycin.

Dr. Sytkowski brings to Callisto considerable experience with clinical development of cancer drugs from Phase I through Phase III which he has gained through experience with a number of leading pharmaceutical and biotechnology companies.

Dr. Sytkowski is Director of the Laboratory for Cell and Molecular Biology Division of Hematology and Oncology at Beth Israel Deaconess Medical Center Harvard Medical School. Dr. Sytkowski who is board certified in internal medicine received his M.D. degree from the Medical College of Wisconsin followed by an internship and medical residency at the Peter Bent Brigham Hospital and a hematology/oncology fellowship at the Boston Children's Hospital and the Dana Farber Cancer Institute all at Harvard Medical School.

Dr. Sytkowski has been an Associate Professor of Medicine at Harvard Medical School since 1986 and a Staff Physician at Beth Israel Deaconess Medical Center Boston. Dr. Sytkowski has been in active practice in the areas of internal medicine and of pediatric and adult oncology and hematology and in the past 10 years has been an advisor to numerous companies on the design and execution of clinical trials.